Systematic review of the values and preferences regarding the use of injectable pre‐exposure prophylaxis to prevent HIV acquisition
Rattachement africain : us, ca, ch, th. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
INTRODUCTION: Pre-exposure prophylaxis (PrEP) is an important HIV prevention option. Two randomized trials have provided efficacy evidence for long-acting injectable cabotegravir (CAB-LA) as PrEP. In considering CAB-LA as an additional PrEP modality for people at substantial risk of HIV, it is important to understand community response to injectable PrEP. We conducted a systematic review of values, preferences and perceptions of acceptability for injectable PrEP to inform global guidance. METHODS: We searched nine databases and conference websites for peer-reviewed and grey literature (January 2010-September 2021). There were no restrictions on location. A two-stage review process assessed references against eligibility criteria. Data from included studies were organized by constructs from the Theoretical Framework of Acceptability. RESULTS: We included 62 unique references. Most studies were observational, cross-sectional and qualitative. Over half of the studies were conducted in North America. Men who have sex with men were the most researched group. Most studies (57/62) examined injectable PrEP, including hypothetical injectables (55/57) or placebo products (2/57). Six studies examined CAB-LA specifically. There was overall interest in and often a preference for injectable PrEP, though there was variation within and across groups and regions. Many stakeholders indicated that injectable PrEP could help address adherence challenges associated with daily or on-demand dosing for oral PrEP and may be a better lifestyle fit for individuals seeking privacy, discretion and infrequent dosing. End-users reported concerns, including fear of needles, injection site pain and body location, logistical challenges and waning or incomplete protection. DISCUSSION: Despite an overall preference for injectable PrEP, heterogeneity across groups and regions highlights the importance of enabling end-users to choose a PrEP modality that supports effective use. Like other products, preference for injectable PrEP may change over time and end-users may switch between prevention options. There will be a greater understanding of enacted preference as more end-users are offered anti-retroviral (ARV)-containing injectables. Future research should focus on equitable implementation, including real-time decision-making and how trained healthcare providers can support choice. CONCLUSIONS: Given overall acceptability, injectable PrEP should be included as part of a menu of prevention options, allowing end-users to select the modality that suits their preferences, needs and lifestyle.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Systematic review of the values and preferences regarding the use of injectable pre‐exposure prophylaxis to prevent HIV acquisition
- Date Crossref
- 01/07/2023
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Family Health International 360 pays non établi dans la noticeOrganisation à but non lucratif
-
University of California Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
San Francisco AIDS Foundation pays non établi dans la noticeOrganisation à but non lucratif
-
Kensington Health pays non établi dans la noticeOrganisation à but non lucratif
-
Atmospheric and Space Technology Research Associates (United States) pays non établi dans la noticeEntreprise
-
World Health Organization pays non établi dans la noticeOrganisme public
-
UNICEF East Asia and Pacific Regional Office pays non établi dans la noticeOrganisation à but non lucratif
-
Global Health and Population Research FHI 360 Durham North Carolina USA pays non établi dans la noticeInstitution
-
ASTRA Consulting Kensington California USA pays non établi dans la noticeInstitution
-
UNAIDS Regional Office for Asia and the Pacific Bangkok Thailand pays non établi dans la noticeInstitution
Family Health International 360, Department of Medicine — University of California et San Francisco AIDS Foundation, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.